Sanuwave Health Updates Second Quarter 2026 Guidance

$SNWVPress releaseJun 16, 2026, 8:00 AM ETRead the release

Sanuwave Health lowered its Q2 2026 revenue guidance to a range of $8.5 million to $9.5 million, citing adverse market conditions for its Ultramist capital equipment. CEO Morgan Frank noted that widespread CMS reimbursement clawbacks have forced wound care practice closures, resulting in a secondary market for used systems that is cannibalizing new sales.

Key figures

Revenue: $8.5 - $9.5 million
Guidance: Q2 2026 revenue $8.5 - $9.5 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.